Head of Research Group

•  Researcher ID
• CV
• Publications

---

Senior Scientist

• CV
• Publications

---

PostDoc

• CV
• Publications

---

Technical Assistance

• Publications

---

PhD Students

My fascination with science began early and led me to pursue a BSc in Bioengineering with a specialization in Applied Biotechnology at the Hungarian University of Agriculture and Life Sciences in Budapest, where I graduated in 2021. During my bachelor’s studies, I spent one semester abroad through the Erasmus program at Wageningen University in the Netherlands. I continued my education with a Master’s degree in Medical Biology at the University of Salzburg, which I completed in 2025. Alongside my academic studies, I consistently worked in professional settings to gain hands-on experience. I spent two years as a laboratory analyst at EGIS, a leading pharmaceutical company and part of the Servier Group, where I honed my analytical skills. After completing my bachelor’s degree, I joined Pharmgenetix, an innovative molecular diagnostics startup focused on personalized medicine. Over the course of more than three years, I worked there as a laboratory technician, contributing to both routine analytics and research projects. I also conducted the research for my Master’s thesis at Pharmgenetix, titled “Investigation of the Functional Consequences of CYP2D6 Promoter Polymorphisms on Gene Expression.”. 

Saruchi completed her undergraduate degree in microbiology from Gargi College, University of Delhi, India, in 2015. She was enrolled in the Dr. B. R. Ambedkar Center for Biomedical Research (A.C.B.R.), University of Delhi, India, for the master’s degree program in biomedical sciences, which was completed in 2017. She worked as a Research Fellow at Translational Health Science and Technology Institute, India, with a focus on the role of type II toxin-antitoxin systems in Mycobacterium tuberculosis persistence. She then worked as a senior research fellow at the CSIR Institute of Genomics and Integrative Biology (IGIB), India, where she characterized the novel mutation in the PRKG2 gene responsible for acromesomelic skeletal dysplasia. As part of a three-month EMBO exchange program, she also worked at the University of Helsinki, Finland, where she learned gene editing of patient-specific mutations using CRISPR/Cas9 gene editing technology in patient-derived iPSCs.

• Publications

Paul earned his Bachelor of Engineering (B.Eng.) degree in 2016 from the Munich University of Applied Sciences. During his bachelor thesis, he worked at the Institute for Translational Cardiac Surgery at the German Heart Centre Munich, where he focused on investigating the direct reprogramming of murine primary fibroblasts into induced cardiac progenitor cells. For his Master’s studies, Paul moved to the Technical University of Munich, completing a Master of Science (M.Sc.) in Molecular Biotechnology in 2024. As part of his academic journey, he undertook a six-month industrial internship in the Cell Technologies department at Roche in Penzberg and participated in a semester abroad at the Faculty of Sciences, University of Lisbon. His master thesis was conducted at the Institute of Molecular Oncology and Functional Genomics at TranslaTUM, where he worked on validating a CasRx-based lncRNA screening platform. In 2025, Paul joined Silja Weßler’s group, where his research focuses on developing organoid-based advanced infection models for carcinogenic pathogens.

---

MasterstudentInnen

---

StudienassistentInnen